Trüb, Marta
Uhlenbrock, Franziska
Claus, Christina
Herzig, Petra
Thelen, Martin https://orcid.org/0000-0002-2785-9726
Karanikas, Vaios
Bacac, Marina
Amann, Maria
Albrecht, Rosemarie
Ferrara-Koller, Claudia
Thommen, Daniela
Rothschield, Sacha
Savic Prince, Spasenija
Mertz, Kirsten D
Cathomas, Gieri
Rosenberg, Robert
Heinzelmann-Schwarz, Viola
Wiese, Mark
Lardinois, Didier
Umana, Pablo
Klein, Christian
Laubli, Heinz https://orcid.org/0000-0002-8910-5620
Kashyap, Abhishek S
Zippelius, Alfred https://orcid.org/0000-0003-1933-8178
Clinical trials referenced in this document:
Documents that mention this clinical trial
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
https://doi.org/10.1136/jitc-2019-000238
Documents that mention this clinical trial
Role of Fcγ receptors in HER2-targeted breast cancer therapy
https://doi.org/10.1136/jitc-2021-003171
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
https://doi.org/10.1136/jitc-2019-000238
Documents that mention this clinical trial
Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer
https://doi.org/10.1136/jitc-2019-000238
Funding for this research was provided by:
Roche Innovation Fund
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_188576)
Krebsliga Beider Basel
Wilhelm Sander-Stiftung
University of Basel Research Fund
Basel Translational Medicine Hub